Author correction to ‘Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling’ [Acta Pharmaceutica Sinica B 12 (2022) 1198–1212]
Main Authors: | Yunhao Wu, Xiu Yu, Yuwei Wang, Yalin Huang, Jiahui Tang, Shuaishuai Gong, Siyu Jiang, Yuanli Xia, Fang Li, Boyang Yu, Yuanyuan Zhang, Junping Kou |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-07-01
|
Series: | Acta Pharmaceutica Sinica B |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383522001629 |
Similar Items
-
Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling
by: Yunhao Wu, et al.
Published: (2022-03-01) -
Author correction to ‘Approved HIV reverse transcriptase inhibitors in the past decade’ [Acta Pharmaceutica Sinica B 12 (2022) 1567–1590]
by: Guangdi Li, et al.
Published: (2023-08-01) -
Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11 (2021) 1903–1913]
by: Ziru Yu, et al.
Published: (2023-08-01) -
Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11(2021) 1903–1913]
by: Ziru Yu, et al.
Published: (2023-02-01) -
Author correction to “Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors” [Acta Pharmaceutica Sinica B 12 (2022) 4501–4518]
by: Yuling Mao, et al.
Published: (2024-03-01)